Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
ANG LIFESCIENCES INDIA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ANG LIFESCIENCES INDIA Mar-23 |
ADCOCK INGRAM Jun-14 |
ANG LIFESCIENCES INDIA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 276 | 314 | - | |
Low | Rs | 72 | 226 | - | |
Sales per share (Unadj.) | Rs | 168.4 | 93.4 | - | |
Earnings per share (Unadj.) | Rs | -0.2 | -23.5 | - | |
Cash flow per share (Unadj.) | Rs | 7.0 | -19.5 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 66.0 | 73.3 | - | |
Shares outstanding (eoy) | m | 13.06 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.0 | 2.9 | 35.7% | |
Avg P/E ratio | x | -867.2 | -11.5 | 7,552.5% | |
P/CF ratio (eoy) | x | 25.0 | -13.9 | -180.4% | |
Price / Book Value ratio | x | 2.6 | 3.7 | 71.5% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 2,272 | 45,603 | 5.0% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 240 | 2,862 | 8.4% | |
Avg. sales/employee | Rs Th | 0 | 3,671.4 | - | |
Avg. wages/employee | Rs Th | 0 | 666.7 | - | |
Avg. net profit/employee | Rs Th | 0 | -925.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 2,199 | 15,761 | 14.0% | |
Other income | Rs m | 97 | 110 | 88.1% | |
Total revenues | Rs m | 2,296 | 15,872 | 14.5% | |
Gross profit | Rs m | 147 | -2,731 | -5.4% | |
Depreciation | Rs m | 94 | 680 | 13.8% | |
Interest | Rs m | 125 | 427 | 29.2% | |
Profit before tax | Rs m | 26 | -3,728 | -0.7% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 29 | 233 | 12.4% | |
Profit after tax | Rs m | -3 | -3,971 | 0.1% | |
Gross profit margin | % | 6.7 | -17.3 | -38.7% | |
Effective tax rate | % | 110.0 | -6.2 | -1,760.2% | |
Net profit margin | % | -0.1 | -25.2 | 0.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 1,852 | 11,544 | 16.0% | |
Current liabilities | Rs m | 1,623 | 6,495 | 25.0% | |
Net working cap to sales | % | 10.4 | 32.0 | 32.5% | |
Current ratio | x | 1.1 | 1.8 | 64.2% | |
Inventory Days | Days | 1 | 111 | 0.8% | |
Debtors Days | Days | 1,380 | 124 | 1,113.6% | |
Net fixed assets | Rs m | 887 | 6,729 | 13.2% | |
Share capital | Rs m | 131 | 73 | 178.4% | |
Net worth | Rs m | 862 | 12,371 | 7.0% | |
Long term debt | Rs m | 205 | 4,347 | 4.7% | |
Total assets | Rs m | 2,756 | 23,369 | 11.8% | |
Interest coverage | x | 1.2 | -7.7 | -15.7% | |
Debt to equity ratio | x | 0.2 | 0.4 | 67.8% | |
Sales to assets ratio | x | 0.8 | 0.7 | 118.3% | |
Return on assets | % | 4.4 | -15.2 | -29.2% | |
Return on equity | % | -0.3 | -32.1 | 0.9% | |
Return on capital | % | 14.2 | -19.8 | -71.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 264 | 1,345 | 19.6% | |
From Investments | Rs m | -93 | -413 | 22.6% | |
From Financial Activity | Rs m | -171 | 3,945 | -4.3% | |
Net Cashflow | Rs m | 0 | 4,878 | -0.0% |
Compare ANG LIFESCIENCES INDIA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare ANG LIFESCIENCES INDIA With: SYNCOM HEALTHCARE MAKERS LAB. HESTER BIOSCIENCES PANCHSHEEL ORG MARKSANS PHARMA.
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.